Agile Therapeutics, Inc. | $AGRX Stock | Shares Nosedive Despite Positive Top-Line Phase 3 Results For Twirla

1
687

Agile Therapeutics, Inc. (NASDAQ: AGRX)

 

 

Agile Therapeutics, Inc.(AGRX), a specialty pharmaceutical company yesterday announced positive top-line results from its Phase 3 SECURE clinical trial of Twirla. Agile Therapeutics plans to resubmit its new drug application for Twirla during the first half 2017 on the basis of the trials results.

 

Agile Therapeutics, Inc. Senior VP AND CEO’s  Comments

“We have now successfully completed our clinical trials for Twirla and added substantial clinical data to our existing body of information, in particular around the safety profile for the patch.  SECURE represented an excellent opportunity to further examine the safety and effectiveness of Twirla in a trial designed to meet the FDA’s recommendations for current contraceptive studies and focused on improved study conduct,” said Dr. Elizabeth Garner, Senior Vice-President and Chief Medical Officer of Agile Therapeutics.  “We believe we have addressed the clinical questions raised by the FDA in its CRL, and also produced important public health data in obese women that the FDA called for in its 2015 publication.  We look forward to discussing these topics with the Agency.  We greatly appreciate the hard work and dedication from our clinical team and wish to thank the clinical investigators, their staff, and most importantly, the 2032 women who participated in the SECURE trial.”  “We are very pleased with having achieved this critical milestone for Agile Therapeutics,” said Al Altomari, President and Chief Executive Officer of Agile.  “Now that we have successfully completed SECURE, we are focused on preparing the resubmission of our NDA and continuing our progress towards seeking approval of Twirla and commercializing Twirla in the United States.”  Globe Newswire

 

AGRX Technical Analysis

Agile Therapeutics

Agile Therapeutics opened trading yesterday at $5.77 which was up from the previous day’s trading close of $5.70. AGRX closed trading yesterday at $5.00 and crashed down after market to $1.39, equivalent to a 72% decrease from the closing price. Taking a look at the daily chart we can see that we are in uncharted territory as with the spike down AGRX is currently trading at all time lows. Taking a closer look at the daily chart we can see that before the spike down Agile Therapeutics had already been in an overall downward trend dating back to November 8th when it traded at $7.68.

Agile Therapeutics has a float of 10.02 million shares and traded 26.26 times the normal daily trading volume on Tuesday. For trading purposes, I would like to see AGRX open trading on Wednesday below $2.50 and if it does I would be looking to take a short position at the bell. My stop loss would be $0.20 from my entry position fearing anything more than that and the stock would start to fill in the gap down.

 

Agile Therapeutics Profile

Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.  Yahoo Finance

 

 

IMAGE CREDIT

SHARE
Previous articleMobileye N.V. | $MBLY Stock | Shares Climb Up On Announcement Of New Partnership With HERE
Next articleTesla Motors | $TSLA Stock | Shares Get A Boost On Battery Production Outlook
You can reach us at our TickerTV Office via support@ticker.tv or by phone (917) 720-3537. Legal Disclaimer – This is not meant to be a recommendation to buy or to sell securities nor an offer to buy or sell securities. Before selling or buying any stock or other investment you should consult with a qualified broker or other financial professional. The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author has no business relationship with any company whose stock is mentioned in this article nor is receiving compensation from any of the companies mentioned.

1 COMMENT

LEAVE A REPLY